Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from PepGen Inc. ( (PEPG) ).
On May 28, 2025, PepGen Inc. announced its decision to discontinue the development of its Duchenne muscular dystrophy (DMD) programs following disappointing results from the CONNECT1-EDO51 trial, where the PGN-EDO51 treatment did not achieve target dystrophin levels. Despite the well-tolerated safety profile, the company will wind down all DMD-related research and development activities. PepGen will now focus on advancing its promising myotonic dystrophy type 1 (DM1) program, which has shown robust target engagement and favorable safety profile in early trials. The company plans to report further data from its ongoing DM1 clinical trials in late 2025 and early 2026, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (PEPG) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on PepGen Inc. stock, see the PEPG Stock Forecast page.
Spark’s Take on PEPG Stock
According to Spark, TipRanks’ AI Analyst, PEPG is a Underperform.
PepGen Inc.’s overall score reflects significant financial challenges, with limited revenue and continued losses. While technical indicators are mixed, the valuation remains unattractive due to negative earnings. Recent corporate events, including promising trial results and board expansions, offer some positive momentum but are insufficient to offset the financial concerns.
To see Spark’s full report on PEPG stock, click here.
More about PepGen Inc.
PepGen is a clinical-stage biotechnology company focused on developing next-generation oligonucleotide therapies aimed at treating severe neuromuscular and neurological diseases. The company leverages its Enhanced Delivery Oligonucleotide (EDO) technology platform to improve the uptake and activity of conjugated oligonucleotide therapeutics, targeting the root cause of serious diseases.
Average Trading Volume: 356,551
Technical Sentiment Signal: Sell
Current Market Cap: $48.1M
For an in-depth examination of PEPG stock, go to TipRanks’ Stock Analysis page.